Excise tax increases on drug imports to India should have little impact on the current robust growth of the Indian pharmaceutical industry, according to a report by global analytics company Crisil. The firm projects a domestic growth rate year-over-year increase of 16% to 17% through 2014, coupled with export increases of 17%, as India increasingly taps into generics and manufacturing opportunities for bulk drugs.
Tax increase should have minimal impact on India's drug industry
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||